Trial Of Erlotinib With Or Without PF-3512676 In Advanced Non Small Cell Lung Cancer

• Drug: PF-3512676 + Erlotinib
  

  PF-3512676 0.2 mg/kg subcutaneously on days 1, 8 and 15 of each 21 day cycle until disease progression or unacceptable toxicity.

  Erlotinib 150 mg orally daily (21 day cycles) until disease progression or unacceptable toxicity

• Drug: Erlotinib
  
  Erlotinib 150 mg orally daily (21 day cycles) until disease progression or unacceptable toxicity
  Other Name: Tarceva

• Experimental: A
  
  Standard of Care chemotherapy plus experimental intervention (PF-3512676)
  Intervention: Drug: PF-3512676 + Erlotinib
• Active Comparator: B
  
  Standard of Care chemotherapy
  Intervention: Drug: Erlotinib

Inclusion Criteria:

• Advanced, EGFR-positive NSCLC
• ECOG Performance Status 0, 1 or 2
• Measurable disease

Exclusion Criteria:

• Known CNS metastasis
• Pre-existing autoimmune or antibody mediated disease